GlassScriptPhysician profile
Jill E Heytens
NPI 1972625994
$1,709.59
in general payments reported to CMS, 2019-2025
25 companies · $1,012 in 2025
The $1,012 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.33 · 2020: $49.10 · 2021: $138 · 2022: $110 · 2023: $80.58 · 2024: $290 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,382.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $286.43 | 2021-2025 | |
| Axsome Therapeutics, INC. | $217.13 | 2025 | Symbravo, Sunosi |
| Allergan, INC. | $203.77 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $180.89 | 2024-2025 | |
| Genentech USA, INC. | $134.27 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Sk Life Science, INC. | $134.12 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $68.58 | 2025 | Ultomiris |
| Biogen, INC. | $66.48 | 2025 | Tysabri, Vumerity |
| Otsuka America Pharmaceutical, INC. | $49.41 | 2025 | Rexulti |
| Avadel Cns Pharmaceuticals, LLC | $49.14 | 2025 | Lumryz |
| Orthofix Medical, INC. | $48.47 | 2024 | Spinal-Stim, Cervical-Stim |
| Amneal Pharmaceuticals LLC | $31.36 | 2025 | Crexont |
| Lilly USA, LLC | $30.55 | 2025 | Kisunla, Amyvid |
| Tonix Medicines, INC. | $24.22 | 2025 | Zembrace Symtouch |
| Teva Pharmaceuticals USA, INC. | $20.58 | 2025 | Austedo Xr |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $20.22 | 2025 | |
| Ucb, INC. | $19.03 | 2024 | Briviact |
| Biohaven Pharmaceutical Holding Company LTD. | $17.73 | 2022 | |
| Pfizer INC. | $17.41 | 2024 | |
| Abbott Laboratories | $16.44 | 2021 | |
| Lundbeck LLC | $15.98 | 2024 | Vyepti |
| Idorsia Pharmaceuticals US INC | $15.74 | 2024 | Quviviq |
| Argenx US, INC. | $14.53 | 2025 | Vyvgart Hytrulo |
| Aucta Pharmaceuticals, INC. | $13.89 | 2025 | Motpoly Xr |
| Corium, LLC | $13.22 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Heytens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.